D9Z.F Clínica Baviera S.A

Healthcare Biotechnology Frankfurt Exchange
52.40 EUR
Close of Nov 12, 2026
39.07 61.40
Market cap
EUR 840M
P/E
18.3x
P/B
7.44x
ROE
47.0%
Dividend yield
3.14%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is D9Z.F undervalued?

Graham number
Price52.40
Graham value21.32
Premium145.8%

D9Z.F trades 145.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clínica Baviera S.A fundamental analysis

No fundamental analysis for Clínica Baviera S.A yet.

Clínica Baviera S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clínica Baviera S.A

Clínica Baviera, S.A., a medical company, provides ophthalmologic medicine services in Spain, Germany, and rest of Europe. The company offers refractive, presbyopia, and cataract surgeries; and oculoplastia, corneal disease, dry eye, strabismus, pediatric ophthalmology, glaucoma, neuro-ophthalmological, disorders, and blepharoplasty treatments. It also provides external and internal consultations, surgery treatments, and rehabilitation services. The company was formerly know…

Full company profile